Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily single-pill regimen
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
For people with relapsed or refractory diffuse large B-cell lymphoma
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
Subscribe To Our Newsletter & Stay Updated
